MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice

Aguilo, N. (Universidad de Zaragoza) ; Uranga, S. (Universidad de Zaragoza) ; Marinova, D. (Universidad de Zaragoza) ; Monzon, M. (Universidad de Zaragoza) ; Badiola, J. (Universidad de Zaragoza) ; Martin, C. (Universidad de Zaragoza)
MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice
Financiación H2020 / H2020 FundsFinanciación FP7 / Fp7 Funds
Resumen: Development of novel more efficient preventive vaccines against tuberculosis (TB) is crucial to achieve TB eradication by 2050, one of the Millennium Development Goals (MDG) for the current century. MTBVAC is the first and only live attenuated vaccine based on a human isolate of Mycobacterium tuberculosis developed as BCG-replacement strategy in newborns that has entered first-in-human adult clinical trials. In this work, we characterize the safety, immunogenicity and protective efficacy of MTBVAC in a model of newborn C57/BL6 mice. Our data clearly indicate that MTBVAC is safe for newborn mice, and does not affect animal growth or organ development. In addition, MTBVAC-vaccinated mice at birth showed enhanced immunogenicity and better protection against M. tuberculosis challenge in comparison with BCG.
Idioma: Inglés
DOI: 10.1016/j.tube.2015.10.010
Año: 2016
Publicado en: TUBERCULOSIS 96 (2016), 71-74
ISSN: 1472-9792

Factor impacto JCR: 2.873 (2016)
Categ. JCR: MICROBIOLOGY rank: 53 / 124 = 0.427 (2016) - Q2 - T2
Categ. JCR: RESPIRATORY SYSTEM rank: 23 / 59 = 0.39 (2016) - Q2 - T2
Categ. JCR: IMMUNOLOGY rank: 82 / 150 = 0.547 (2016) - Q3 - T2

Factor impacto SCIMAGO: 1.224 - Immunology (Q2) - Microbiology (medical) (Q2) - Microbiology (Q2) - Infectious Diseases (Q2)

Financiación: info:eu-repo/grantAgreement/ES/FECYT/INNOCASH-INC-098
Financiación: info:eu-repo/grantAgreement/EC/FP7/241745/EU/Discovery and preclinical development of new generation tuberculosis vaccines/NEWTBVAC
Financiación: info:eu-repo/grantAgreement/EC/H2020/643381/EU/TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development/TBVAC2020
Financiación: info:eu-repo/grantAgreement/ES/MINECO/BIO2011-23555
Financiación: info:eu-repo/grantAgreement/ES/MINECO/BIO2014-5258P
Tipo y forma: Article (Published version)
Área (Departamento): Área Microbiología (Dpto. Microb.Med.Pr.,Sal.Públ.)
Área (Departamento): Area Histología (Dpto. Anatom.Histolog.Humanas)
Área (Departamento): Área Sanidad Animal (Dpto. Patología Animal)
Área (Departamento): Proy. investigación HQA (Dpto. Microb.Med.Pr.,Sal.Públ.)


Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material.


Exportado de SIDERAL (2020-02-21-13:23:07)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Articles



 Record created 2016-02-04, last modified 2020-02-21


Versión publicada:
 PDF
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)